• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      New Autism Treatment Drug, KM-391 is in Development

      Posted AtHuliq.com

      Breaking news was released today regarding the Cellceutix Corporation, a preclinical cancer, autism and anti-inflammatory drug developer, and its new rights to pursue the development of the drug KM-391, for the treatment of autism spectrum disorder. The drug is said to work on the "Neonatal serotonin depletion and reduced plasticity of the brain which are salient features observed in Autism," according to Cellceutix.

      George Evans, the CEO of Cellceutix talked about the company's new compound KM-391 in attempt to get shareholders of the company excited about the new development. The compound, KM-391 was acquired by Cellceutix in December, 2009 and in January 2010, an article was published by Business Week about the "drug industry is finally gearing up for an assault on autism."

      Mr. Evans stated, "Autism is a condition where there is loss in certain brain functions, which leads to behavior disorder. The present scientific research directs us to a few things. One being the plasticity of brain tissue, the second being nerve tangling in the brain and the third being uneven production of serotonin, all which may have a significant effect on evolution and degree of severity of autism in any particular individual."

      Since there are currently no drugs on the market that are approved to treat symptoms of autism, Cellceutix is working as rapidly as possible to learn more about the potential for the development of KM-391 and is very encouraged about it thus far. The drug was first developed as a small molecule in India and now is being "synthesized in the United States for continued research".

      There is very promising data on the drug KM-391. Although KM-391 has not been studied in humans at this time, it has already showed positive results in animal studies. Cellceutix stated, "Preliminary testing of KM 391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects in the long-term administration of KM 391 in mice."

      The FDA has yet to approve any drugs for autism and Cellceutix is hoping to be the first company that becomes approved with a successful drug which the face of autism spectrum disorder forever. That drug is KM-391.

      Mr. Evans stated, "We are extremely excited about the data on KM-391 and the potential for the compound in this area of urgent medical need. Diagnoses of autism are rising dramatically and the disease takes a terrible toll on families. There is a critical need for new treatments for autism and we are pleased to be part of the effort to find them."

      July 13, 2010


      Share this Article!

    Back to top^